Clinical evaluation of protein C activity in sepsis-induced disseminated intravascular coagulatio
- Conditions
- Sepsis-induced disseminated intravascular coagulation
- Registration Number
- JPRN-UMIN000018984
- Lead Sponsor
- ational Hospital Organization Kumamoto Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
We exclude the following patients who may have conditions affecting prognosis other than infection, or affecting protein C activity. 1) Patients with hematopoietic malignancy such as leukemia, or solid cancer. 2) Patients having immunodeficiency disorder, such as myelodysplastic syndrome, myeloproliferative disorder, and acquired immunodeficiency syndrome. 3) Patients having severe liver cirrhosis (Child-Pugh B or C). 4) Patients having exogenous disease such as severe injury, severe burn,or heat stroke. Severe injury is defined as conditions having 3 points or more in at least one body part of AIS90 Update98. Severe burn is defined as conditions having 3 points or more in at least one body part of AIS90 Update98. Heat stroke is defined as grade III in Yasuoka classification. 5) Patients having protein C deficiency disease. 6) Patients or legal representative refuse written informed consent. 7) Patients receiving anti-DIC therapy at the time of entry, such as heparin (unfractionated heparin, low molecular weight heparin), heparinoid, antithrombin, recombinant human thrombomodulin, serine protease inhibitor (gabexate mesilate, nafamostat mesilete).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality on day 30
- Secondary Outcome Measures
Name Time Method Recovery from DIC on day 3 and day6 ARDS